Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16%. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that activates multiple signaling pathways that stimulate transformed growth and invasion, and maintain a KRAS LADC tumor-initiating cell (TIC) phenotype. PKCι inhibitors used alone and in strategic combination show promise as new therapeutic approaches to treatment of KRAS LADC. These novel drug combinations may improve clinical management of KRAS LADC.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalSmall GTPases
DOIs
StateAccepted/In press - Jun 30 2016

Fingerprint

Protein Kinases
Protein Kinase C
Drug Combinations
Tumors
Lung Neoplasms
Neoplastic Stem Cells
Protein C Inhibitor
Protein Kinase Inhibitors
Cause of Death
Survival Rate
Phenotype
Adenocarcinoma of lung
Growth
Neoplasms
Therapeutics

Keywords

  • lung adenocarcinoma
  • oncogenic Kras
  • Protein Kinase Ciota
  • therapeutic targeting

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC. / Fields, Alan P; Ali, Syed A.; Justilien, Verline; Murray, Nicole R.

In: Small GTPases, 30.06.2016, p. 1-7.

Research output: Contribution to journalArticle

@article{d127bfd9a0ff48d0b0209819ff342e8f,
title = "Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC",
abstract = "Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16{\%}. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that activates multiple signaling pathways that stimulate transformed growth and invasion, and maintain a KRAS LADC tumor-initiating cell (TIC) phenotype. PKCι inhibitors used alone and in strategic combination show promise as new therapeutic approaches to treatment of KRAS LADC. These novel drug combinations may improve clinical management of KRAS LADC.",
keywords = "lung adenocarcinoma, oncogenic Kras, Protein Kinase Ciota, therapeutic targeting",
author = "Fields, {Alan P} and Ali, {Syed A.} and Verline Justilien and Murray, {Nicole R}",
year = "2016",
month = "6",
day = "30",
doi = "10.1080/21541248.2016.1194953",
language = "English (US)",
pages = "1--7",
journal = "Small GTPases",
issn = "2154-1248",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC

AU - Fields, Alan P

AU - Ali, Syed A.

AU - Justilien, Verline

AU - Murray, Nicole R

PY - 2016/6/30

Y1 - 2016/6/30

N2 - Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16%. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that activates multiple signaling pathways that stimulate transformed growth and invasion, and maintain a KRAS LADC tumor-initiating cell (TIC) phenotype. PKCι inhibitors used alone and in strategic combination show promise as new therapeutic approaches to treatment of KRAS LADC. These novel drug combinations may improve clinical management of KRAS LADC.

AB - Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16%. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that activates multiple signaling pathways that stimulate transformed growth and invasion, and maintain a KRAS LADC tumor-initiating cell (TIC) phenotype. PKCι inhibitors used alone and in strategic combination show promise as new therapeutic approaches to treatment of KRAS LADC. These novel drug combinations may improve clinical management of KRAS LADC.

KW - lung adenocarcinoma

KW - oncogenic Kras

KW - Protein Kinase Ciota

KW - therapeutic targeting

UR - http://www.scopus.com/inward/record.url?scp=84978945624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978945624&partnerID=8YFLogxK

U2 - 10.1080/21541248.2016.1194953

DO - 10.1080/21541248.2016.1194953

M3 - Article

SP - 1

EP - 7

JO - Small GTPases

JF - Small GTPases

SN - 2154-1248

ER -